KR930702506A - Hepatitis C Virus Antibody - Google Patents

Hepatitis C Virus Antibody

Info

Publication number
KR930702506A
KR930702506A KR1019930701073A KR930701073A KR930702506A KR 930702506 A KR930702506 A KR 930702506A KR 1019930701073 A KR1019930701073 A KR 1019930701073A KR 930701073 A KR930701073 A KR 930701073A KR 930702506 A KR930702506 A KR 930702506A
Authority
KR
South Korea
Prior art keywords
antibody
plasma
hepatitis
virus
produced
Prior art date
Application number
KR1019930701073A
Other languages
Korean (ko)
Inventor
에프. 밀러 말론
알. 레스니에프스키 리차드
에이. 피터슨 데이비드
휴 브라이스 워렌
Original Assignee
찰스 엠. 브록
애보트 래보라토리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 찰스 엠. 브록, 애보트 래보라토리즈 filed Critical 찰스 엠. 브록
Publication of KR930702506A publication Critical patent/KR930702506A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 감염 환자로부터 분리된 C형 간염 바이러스 입자와 관련된 항원 또는 HCV 응집 항원과 선택적으로 결합하는 폴리클로닐 및 모노클로날 항체, 및 HCV가 부분적으로 정제되는 공정을 포함한, 감염 환자로부터 C형 간염 바이러스를 분리하는데 이용될 수 있는 방법에 관한 것이다. 또한 진단 면역 검정법에서의 이들 항체의 용도도 기술되어 있다.The present invention provides polyclonal and monoclonal antibodies that selectively bind to antigens associated with hepatitis C virus particles isolated from infected patients or HCV aggregated antigens, and a process in which HCV is partially purified. A method that can be used to isolate hepatitis virus. The use of these antibodies in diagnostic immunoassays is also described.

Description

C형 간염 바이러스 항체Hepatitis C Virus Antibody

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (12)

전체 바이러스 입자와 관련될 수 있고 침팬지 및 사람으로 이루어진 그룹중에서 선택되는 포유동물에서 면역 반응을 나타내는, 하나 이상의 C형 간염 바이러스 항원과 선택적으로 결합할 수 있는 항체.An antibody capable of selectively binding to one or more hepatitis C virus antigens, which may be associated with whole virus particles and exhibit an immune response in a mammal selected from the group consisting of chimpanzees and humans. 제1항에 있어서, 항체가 모노클로날 항체 또는 폴리클로날 항체인 항체.The antibody of claim 1, wherein the antibody is a monoclonal antibody or polyclonal antibody. 제1항에 있어서, 하이브리도마 세포에 의해 생성된 항체.The antibody of claim 1, produced by hybridoma cells. 제3항에 있어서, ATCC 번호 HB 10529호 및 제HB 10530호로 이루어진 그룹중에서 선택된 세포주에 의해 생성된 항체.The antibody of claim 3, wherein said antibody is produced by a cell line selected from the group consisting of ATCC Nos. HB 10529 and HB 10530. ATCC 번호 제10529호 및 HB 10530호로 이루어진 그룹중에서 선택된 C형 간염 바이러스와 관련된 항원에 선택적으로 결합하는 항체를 생성할 수 있는 세포주.A cell line capable of producing antibodies that selectively bind antigens associated with hepatitis C virus selected from the group consisting of ATCC Nos. 10529 and HB 10530. (a)혈장 샘플을 원심분리로 청징하게 하고, (b)청징하게된 혈장을 기공 크기가 3.0, 1.0, 0.8, 0.6, 0.4 및 0.2μ순으로 작아지는 일련의 폴리카보네이트 필터를 통해 여과시킨 후, (c)여과된 혈장을 10% 슈크로즈 용액을 통해 펠렛화시키고, (d)펠렛화된 물질을 재현탁시키는 단계를 포함함을 특징으로 하여, 감염 환자로부터 취한 혈장 샘플로부터 감염성 C형 간염 바이러스를 분리하는 방법.(a) clarify the plasma sample by centrifugation, and (b) filter the clarified plasma through a series of polycarbonate filters with pore sizes decreasing in the order of 3.0, 1.0, 0.8, 0.6, 0.4, and 0.2 μ. (c) pelletizing the filtered plasma through a 10% sucrose solution, and (d) resuspending the pelleted material, wherein the infectious hepatitis C is from a plasma sample taken from an infected patient. How to isolate a virus. 제6항에 있어서, 재현탁된 물질의 감염 역가가 약 105CID/㎖를 초과하고, 재현탁된 혈장 샘플의 총 단백질의 약 1% 미만을 차지하는 방법.The method of claim 6, wherein the infectious titer of the resuspended material is greater than about 10 5 CID / ml and comprises less than about 1% of the total protein of the resuspended plasma sample. 제6항의 방법에 따라 제조된, 약 105CID/㎖를 초과하는 감염 역가를 갖는 정제된 혈장에 대한 항체를 생성시킴을 특징으로 하여, 감염 환자로부터 취한 혈장 샘플로부터 분리된 C형 간염 바이러스에 대한 면역 반응에 의해 생성되는 항체를 제조하는 방법.Hepatitis C virus isolated from a plasma sample taken from an infected patient is characterized by producing antibodies against purified plasma having an infection titer of greater than about 10 5 CID / ml, prepared according to the method of claim 6. A method of making an antibody produced by an immune response against. 제1항의 모노클로날 항체를 사용함을 특징으로 하여, 항원에 특이적인 항체와의 선택적 면역 반응에 기초하는, C형 간염 바이러스와 특이적으로 관련된 항원을 검출하는 면역 검정 방법.An immunoassay method for detecting an antigen specifically related to the hepatitis C virus, wherein the monoclonal antibody of claim 1 is used, based on a selective immune response with an antibody specific for the antigen. 제9항에 있어서, 모노클로날 항체가 ATCC 번호 HB 10529호 및 제HB 10530호로 이루어진 그룹중에서 선택된 세포주에 의해 생성되는 검정 방법.The assay of claim 9, wherein the monoclonal antibody is produced by a cell line selected from the group consisting of ATCC Nos. HB 10529 and HB 10530. (a)혈장 샘플을 원심분리로 청징하게 하고, (b)청징하게된 혈장을 차례로 기공 크기가 작아지는 일련의 필터를 통해 여과시킨 후, (c)여과된 혈장을 10% 슈크로즈 용액을 통해 펠렛화시키며, (d)펠렛화된 물질을 재현탁시키는 단계를 포함함을 특징으로 하여, 감염 환자로부터 취한 혈장 샘플로부터 감염성 C형 간염 바이러스를 분리하는 방법.(a) the plasma sample is clarified by centrifugation, (b) the clarified plasma is filtered through a series of filters that in turn decrease in pore size, and (c) the filtered plasma is passed through a 10% sucrose solution. Pelletizing, and (d) resuspending the pelleted material to separate infectious hepatitis C virus from plasma samples taken from infected patients. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930701073A 1990-10-12 1991-10-09 Hepatitis C Virus Antibody KR930702506A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59681190A 1990-10-12 1990-10-12
US07/596,811 1990-10-12
PCT/US1991/007571 WO1992007001A1 (en) 1990-10-12 1991-10-09 Hepatitis c virus antibody

Publications (1)

Publication Number Publication Date
KR930702506A true KR930702506A (en) 1993-09-09

Family

ID=24388816

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701073A KR930702506A (en) 1990-10-12 1991-10-09 Hepatitis C Virus Antibody

Country Status (7)

Country Link
EP (1) EP0552297A1 (en)
JP (1) JPH06502075A (en)
KR (1) KR930702506A (en)
AU (1) AU663064B2 (en)
CA (1) CA2093919A1 (en)
TW (1) TW216797B (en)
WO (1) WO1992007001A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0556320T3 (en) * 1990-11-07 1999-10-18 Abbott Lab Hepatitis C virus monoclonal antibodies and methods for their use
JP3217600B2 (en) * 1994-07-12 2001-10-09 株式会社先端生命科学研究所 Immunoassay for non-A non-B hepatitis virus-related antigen, monoclonal antibody used therein, and hybridoma producing this antibody
ES2377968T3 (en) 2003-04-01 2012-04-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antibodies directed against the hepatitis C virus E1E2 complex and pharmaceutical compositions
NZ579706A (en) 2007-02-21 2012-03-30 Univ Massachusetts Human antibodues against hepatitis C virus (HCV) E2 protein and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU216017B (en) * 1987-11-18 1999-04-28 Chiron Corp. Method for producing hcv-1 polypeptids, hcv-1 polynucleotids, recombinant vectors and host cells, immunoassay kit, vaccines against hepatitis c infections, diagnostics for detecting the infections, and immunoanalitical and virus culturing process
AU632271B2 (en) * 1988-03-30 1992-12-24 Abbott Laboratories Production of monoclonal antibodies specific for non-a, non-b hepatitis infected liver

Also Published As

Publication number Publication date
WO1992007001A1 (en) 1992-04-30
AU663064B2 (en) 1995-09-28
CA2093919A1 (en) 1992-04-13
JPH06502075A (en) 1994-03-10
AU8945791A (en) 1992-05-20
TW216797B (en) 1993-12-01
EP0552297A1 (en) 1993-07-28
EP0552297A4 (en) 1994-02-09

Similar Documents

Publication Publication Date Title
JP4270751B2 (en) Neutralization of polycations in whole blood chromatography devices
Locarnini et al. Solid-phase enzyme-linked immunosorbent assay for detection of hepatitis A-specific immunoglobulin M
FI20021626A (en) Immunoassay reagent and method for the detection of hepatitis C virus (HCV) antibodies
Ruangjirachuporn et al. Circulating immune complexes in serum from patients with dengue haemorrhagic fever.
Pinon et al. An enzyme-linked immuno-filtration assay used to compare infant and maternal antibody profiles in toxoplasmosis
Cox et al. Cytomegaloviremia in children with acute lymphocytic leukemia
NL1008738C2 (en) Solid phase method for antigen and antibody determinations in blood group serology, and test kit.
Pyndiah et al. Simplified chromatographic separation of immunoglobulin M from G and its application to toxoplasma indirect immunofluorescence
Dreesman et al. Production of potent anti-Australia antigen sera of high specificity and sensitivity in goats
CA2049679A1 (en) Hepatitis c assay utilizing recombinant antigens
Thomas Antibodies specific for human T lymphocytes in cold agglutinin and lymphocytotoxic sera
Boonpucknavig et al. Immunofluorescent staining of the surfaces of lymphocytes in suspension from patients with dengue hemorrhagic fever.
Westaway Antibody responses in rabbits to the group B arbovirus Kunjin: Serologic activity of the fractionated immunoglobulins in homologous and heterologous reactions
Vejtorp Enzyme‐linked immunosorbent assay for determination of rubella IgG antibodies
JPH08242849A (en) Getting rid of virus from protein solution by ultrafiltration
KR930702506A (en) Hepatitis C Virus Antibody
Ades et al. Analysis of mononuclear cell surfaces with fluoresceinated Staphylococcal protein A complexed with IgG antibody or heat-aggregated γ-globulin
Gray et al. The rapid serological diagnosis of infectious mononucleosis
Fiorini et al. Increased frequency of antibodies to ubiquitous viruses in essential mixed cryoglobulinaemia.
Penttinen et al. Platelet aggregation and cryo-IgM in the study of hepatitis and immune complex states
Bux et al. Alloimmune neonatal neutropenia resulting from immunization to a high‐frequency antigen on the granulocyte Fc gamma receptor III
Cremer et al. Role of rheumatoid factor in complement fixation and indirect hemagglutination tests for immunoglobulin M antibody to cytomegalovirus
Crawford et al. Epstein-Barr (EB) virus infection in homosexual men in London.
Winiarski Mechanisms in childhood idiopathic thrombocytopenic purpura (ITP)
Booth et al. Cytomegalovlrus complement‐fixing igm antibody

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid